Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Bristol Myers Squibb Reports Success in Pivotal Trial of Psoriasis Drug

By Jim Crumly - Nov 3, 2020 at 2:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The candidate treatment outperformed the blockbuster drug that Amgen bought for $13.4 billion.

Bristol Myers Squibb ( BMY -1.85% ) on Tuesday announced positive results from a phase 3 trial of deucravacitinib in patients with moderate to severe plaque psoriasis. The drug, an oral tyrosine kinase 2 (TYK2) inhibitor, met primary endpoints versus placebo, and showed superiority to Otezla in multiple key secondary endpoints. Celgene sold Otezla to Amgen last year to clear the way for its acquisition by Bristol Myers Squibb.

Bristol Myers Squibb will release more detailed results from the study at a future medical conference, but said more patients achieved a 75% improvement on the Psoriasis Area and Severity Index and a static Physicians Global Assessment score of clear or almost clear after 16 weeks of treatment with the drug than did those in the placebo group. Some secondary endpoints were also met, including superiority to Otezla. There were 666 patients in the study.

Dollar signs spilling out of a pill.

Image source: Getty Images.

Bristol Myers Squibb and Celgene divested Otezla to Amgen for the massive price of $13.4 billion in order to alleviate the Federal Trade Commission's concerns about their merger, and the deal is paying off for Amgen. Otezla is approved for plaque psoriasis and psoriatic arthritis, and is selling at an annual rate of over $2 billion with double-digit growth.

It'll be a while before deucravacitinib starts cutting into Otezla's sales, assuming it's approved, but Bristol Myers Squibb could be filling the gap in its immunology lineup with a superior drug. The pharmaceutical giant has deucravacitinib in phase 2 trials for treating psoriatic arthritis, lupus nephritis, systemic lupus erythematosus, Crohn's disease, and ulcerative colitis.

Editor's note: This article has been updated.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$53.63 (-1.85%) $-1.01
Amgen Inc. Stock Quote
Amgen Inc.
$198.88 (-2.26%) $-4.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.